Glycans and Brain Health: The Sugar-Cognition Connection Behind Neurodegeneration

Explore the intricate relationship between glycans and brain health, uncovering how sugar impacts cognition and contributes to neurodegeneration.

Brain health does not change overnight. Long before memory lapses or cognitive symptoms are noticeable, the immune system is already shifting, and that shift shows up in glycans, the sugar molecules attached to proteins throughout the body. Understanding glycans and brain health means looking at biological age, not just chronological age, as an early, measurable signal of how the brain's environment is changing, well before a clinical diagnosis would ever be considered.
Glycosylation modifies more than half of all proteins in the body, affecting their structure, stability and function. Because glycans are large, complex and highly variable structures, they are notoriously difficult to characterize, and for years they were largely overlooked in disease research. That is changing. Growing interest in glycoproteomics is now revealing how relevant glycans are, not only to disease itself, but to the biological processes that precede it.
New to the science? Start with the basics of what glycans are and how they reveal your biological age and immune health.
The sugar-cognition connection
The link between glycans and brain health runs through inflammation. Chronic, low-grade inflammation, often called inflammaging, is understood to gradually affect the integrity of the blood-brain barrier, the selective boundary that normally shields brain tissue from circulating immune activity. As that barrier becomes more permeable with age or sustained inflammation, peripheral immune signals have a greater opportunity to influence the brain's environment. Glycans sit at the center of this process because they help determine whether circulating antibodies, particularly immunoglobulin G (IgG), behave in a pro-inflammatory or anti-inflammatory way. Tracking how these glycan structures shift over time offers a window into systemic inflammation long before it could plausibly be linked to cognitive symptoms.
This is a different lens to the traditional one. Alzheimer's and Parkinson's disease research has long focused on specific misfolded proteins, tau and alpha-synuclein, as central disease events. That remains useful, established context: alterations in tau glycosylation have been shown to influence its stability and aggregation, and recent research has linked other glycoproteins in cerebrospinal fluid and brain tissue to Parkinson's progression, while a separate study found IgG glycome differences between healthy individuals and people with Parkinson's disease. But protein pathology describes what has already gone wrong. Systemic glycan health describes a process that is measurable years earlier, and is influenced by everyday, modifiable factors.
What IgG glycans reveal about brain and mental health
Blood and brain tissue carry different glycan signatures, and because brain tissue is far harder to access and analyze than blood, most direct evidence on glycosylation within the brain still comes from animal studies. Blood-based IgG glycosylation, by contrast, is well established and highly sensitive to lifestyle, hormones, inflammation and disease. Emerging evidence suggests that Parkinson's disease and depression share similar pro-inflammatory shifts in IgG glycosylation, and similar patterns have also been reported for other neurological and psychiatric conditions, including Alzheimer's disease, dementia and multiple sclerosis, though independent published confirmation for each of these is still emerging. One study identified distinct blood plasma and IgG glycan signatures linked to the severity of major depressive disorder symptoms and to treatment response, reinforcing the idea that immune-linked inflammation runs alongside changes in brain-related symptoms. This overlap is also reflected in the growing conversation around inflammation and menopause-related brain fog.
"Changes in IgG glycosylation start well before the person actually begins to feel that something is wrong."
— Dr. Olga Zaytseva, PhD, Geneticist and Researcher, Genos Glycoscience Research Laboratory
Stress follows a similar pattern. Studies of post-traumatic stress disorder have found altered glycosylation patterns that may reflect vulnerability to further immune dysregulation, adding stress to the list of everyday, glycan-relevant factors worth tracking alongside diet, sleep and hormones.
Biological age as an early warning system
This is where biological age becomes a genuinely predictive tool rather than a retrospective one. Diet, sleep quality and chronic stress all influence IgG glycosylation months to years before any cognitive symptom would appear, which means a rising biological age can flag a shift toward a more pro-inflammatory, less protective glycan profile while there is still time to intervene.
"In many inflammatory diseases, IgG glycans change up to a decade before people are diagnosed with the disease. These molecular changes happen very early, and over time, this becomes a disease."
— Prof. Gordan Lauc, Professor of Biochemistry and Molecular Biology, University of Zagreb, and Co-Founder & Chief Scientific Officer, GlycanAge
Rather than waiting for symptoms and working backward to a diagnosis, tracking glycans allows a more forward-looking approach: monitoring the systemic inflammatory conditions that research increasingly connects to cognitive decline, and adjusting lifestyle or treatment before those conditions have a chance to compound. For anyone already optimizing diet, sleep and training for longevity, this turns biological age from a single data point into an ongoing feedback loop, one that shows whether those daily choices are actually changing the underlying inflammatory picture.
Tracking brain-relevant inflammation over time
Because brain tissue itself cannot be sampled outside a clinical or research setting, IgG glycosylation offers a practical, blood-based way to track these pro-inflammatory shifts. A GlycanAge test uses a simple finger-prick sample, with results generally ready within two to three weeks, to measure IgG glycosylation and reveal a biological age score, offering a window into the systemic inflammation increasingly connected to brain health. Because glycans respond to lifestyle and treatment changes within months, repeat testing at three to four months for pharmaceutical or hormone-based interventions, or six to twelve months for lifestyle changes, allows individuals and clinicians to track whether an intervention is having a measurable, immune-level effect, rather than relying on symptoms alone. In a functional medicine setting, this gives practitioners an objective, immune-level data point to sit alongside subjective reports of brain fog, low mood or fatigue, helping to distinguish which interventions are genuinely shifting a patient's underlying inflammatory trajectory.
How this differs from other biological age or brain health markers
Many longevity tools claim to measure aging, but few connect directly to the immune-driven inflammation increasingly linked to brain health. First- and second-generation epigenetic clocks estimate biological age from DNA methylation patterns, which change slowly and have been shown to vary considerably between two tests on the same person with no intervention in between. Generic blood panels and DNA tests, meanwhile, tend to capture static genetic risk or a single point-in-time snapshot rather than how the immune system is currently behaving. IgG glycosylation sits apart from these approaches: it shifts within months rather than years, responds to real interventions, and reflects the inflammaging that researchers increasingly associate with cognitive decline and neurodegenerative risk.
"We found that glycans were not particularly helpful in predicting chronological age, but what we saw, perhaps not surprisingly, was that glycan age was predictive of health outcomes."
— Dr. Peter Joshi, Chief Scientist, Humanity Health; University of Edinburgh
What might improve glycan-related brain health in future
Diet, exercise and stress management are already known to shift the IgG glycome toward a more anti-inflammatory profile within months. Early-stage research is now examining whether similar dietary interventions could influence glycosylation within brain tissue itself, though this work remains in preclinical, animal-model stages, and no human data exists yet. If confirmed, it would suggest that some of the same lifestyle levers already used to shift biological age through IgG glycosylation could, in time, extend to supporting brain-specific glycan health as well.
Many questions remain about the exact role glycans play in brain function, but the direction is clear. Biological age testing reframes brain health as something to monitor and act on continuously, rather than something to wait and find out about. Those who want to start tracking their own inflammatory and immune aging profile can order a GlycanAge test, while healthcare providers can integrate glycan testing into functional and longevity-focused patient care.
External sources
Lauc G, Pezer M, Rudan I, Campbell H. Mechanisms of disease: the human N-glycome. Biochim Biophys Acta. 2016 Aug;1860(8):1574-82. doi:10.1016/j.bbagen.2015.10.016. PMID: 26500099. Link: https://pubmed.ncbi.nlm.nih.gov/26500099/
Hwang H, Zhang J, Chung KA, Leverenz JB, Zabetian CP, Peskind ER, et al. Glycoproteomics in neurodegenerative diseases. Mass Spectrom Rev. 2010 Jan-Feb;29(1):79-125. doi:10.1002/mas.20221. PMID: 19358229. PMC: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2799547/
Liu F, Zaidi T, Iqbal K, Grundke-Iqbal I, Merkle RK, Gong CX. Role of glycosylation in hyperphosphorylation of tau in Alzheimer's disease. FEBS Lett. 2002 Feb 13;512(1-3):101-6. doi:10.1016/s0014-5793(02)02228-7. PMID: 11852060. Link: https://pubmed.ncbi.nlm.nih.gov/11852060/
Videira PAQ, Castro-Caldas M. Linking glycation and glycosylation with inflammation and mitochondrial dysfunction in Parkinson's disease. Front Neurosci. 2018;12:381. doi:10.3389/fnins.2018.00381. PMID: 29930494. PMC: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999786/
Russell AC, Simurina M, Garcia MT, Novokmet M, Wang Y, Rudan I, et al. The N-glycosylation of immunoglobulin G as a novel biomarker of Parkinson's disease. Glycobiology. 2017 May 1;27(5):501-10. doi:10.1093/glycob/cwx022. PMID: 28334832. Link: https://pubmed.ncbi.nlm.nih.gov/28334832/
Park DI, Stambuk J, Razdorov G, Pucic-Bakovic M, Martins-de-Souza D, Lauc G, et al. Blood plasma/IgG N-glycome biosignatures associated with major depressive disorder symptom severity and the antidepressant response. Sci Rep. 2018 Jan 9;8(1):179. doi:10.1038/s41598-017-17500-0. PMID: 29317657. PMC: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5760622/
Tudor L, Nedic Erjavec G, Nikolac Perkovic M, Konjevod M, Svob Strac D, Uzun S, et al. N-glycomic profile in combat related post-traumatic stress disorder. Biomolecules. 2019 Dec 6;9(12):834. doi:10.3390/biom9120834. PMID: 31817821. PMC: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6995522/
Deris H, Tominac P, Vuckovic F, Briski N, Astrup A, Blaak EE, et al. Effects of low-calorie and different weight-maintenance diets on IgG glycome composition. Front Immunol. 2022;13:995186. doi:10.3389/fimmu.2022.995186. PMID: 36211377. PMC: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535357/
Tijardovic M, Marijancevic D, Bok D, Kifer D, Lauc G, Gornik O, Keser T. Intense physical exercise induces an anti-inflammatory change in IgG N-glycosylation profile. Front Physiol. 2019;10:1522. doi:10.3389/fphys.2019.01522. PMID: 31920720. PMC: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933519/

Turn health content into action
Explore biological age testing for immune health and inflammaging, GlycanAge for personal wellness tracking, and ordering a GlycanAge biological age test.

The Future of Healthcare is Preventative, Personalised, and Powered by Glycans
Whether you’re improving your own health, supporting patients, or driving research, GlycanAge helps you turn science into action.

Autoimmune Disease and Chronic Inflammation: What IgG Glycans Reveal That Standard Labs Don't
Uncover the hidden connections between IgG glycans and autoimmune diseases. Learn how these biomarkers reveal critical information beyond standard lab results.
November 18, 2026
10 minutes

Can You Rebuild a Younger Immune System?
Learn how glycan biomarkers show measurable immune-age reduction from lifestyle and medical interventions, with real repeat-testing data.
November 17, 2026
10 minutes